MedTrace Logo

Impact of Whey and Leucine on Glycaemia in Adults Without Diabetes

NCT03785951 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-12-24

No results posted yet for this study

Summary

Higher than average blood sugar (glucose) levels are linked to an increased risk of developing type 2 diabetes. As such, there is interest in identifying dietary factors that could lower blood glucose to help reduce the number of people with this disease. Findings from some human studies indicate that dairy products, especially a milk protein (whey), may help the control of blood glucose levels. However, there is a need for further studies to confirm these findings in individuals without diabetes but with higher than average blood glucose levels.

Conditions

  • Pre Diabetes

Interventions

DIETARY_SUPPLEMENT

Whey Protein Isolate

Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat. 50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

DIETARY_SUPPLEMENT

Wheat Protein

Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat. 50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

DIETARY_SUPPLEMENT

Wheat Protein with Leucine

Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate. 50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.

Sponsors & Collaborators

  • Barnham Benevolent Foundation

    collaborator UNKNOWN

  • Jason and Daphne Mermikides Charitable Trust

    collaborator UNKNOWN

  • University of Reading

    lead OTHER

Principal Investigators

  • Julie Lovegrove, Professor · University of Reading

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-31
Primary Completion
2020-07-31
Completion
2020-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03785951 on ClinicalTrials.gov